Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis

Starting soon · Phase 2/Phase 3

Conditions studied: Knee Osteoarthritis

In brief

The goal of this Phase II/III, double-blinded, multicenter clinical trial is to assess the clinical efficacy of autologous peripheral blood mononuclear cells (PBMCs) in the management of knee osteoarthritis (KOA). The main questions it aims to answer are: 1. To determine the safety of the PCP-PBMCs injection 2. To compare the long-term efficacy between PCP-PBMCs and methylprednisolone on pain relief and motor function restoration 3. To analyze improving quality of life after the PCP-PBMCs treatment.

Key facts

Study ID
NCT07703280
Run by
DuoGenic StemCells Corporation (DGSC)
People needed
240
Starts
2026-09-30
Expected to finish
2029-12-31
Last updated by the study team
2026-07-20

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.